
    
      This study will enroll chronic kidney disease patients, stage 3 to 5, who have chronic kidney
      disease mineral and bone disease (CKD-MBD)as defined by Kidney Disease Improvement Global
      Outcome (KDIGO) Guidelines. Patients in one center will be randomized to receive oral Vitamin
      D2 soft capsule or Rocaltrol. A total of 200 patients will be enrolled, 100 in the Vitamin D2
      group and 100 in the 1,25(OH)2 Vitamin D3 group. Outcomes will be assessed as proportion of
      patients achieving target blood levels on calcium, phosphorus, parathyroid hormone, and 25
      hydroxyvitamin D. Other outcomes will also be assessed, which include secondary
      hyperparathyroidism (sHPT), vascular calcification, and cardiovascular diseases.
    
  